Flavia P.
- Country
- Italy
- Department
- SCDU Endocrinology
Research Overview
- A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients with Partial Lipodystrophy
- Open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia
Data & Insights
Has run more than one trial at 4 of 21 partner sites.
Specializations
Metabolic Disorders
The investigator specializes in the therapeutic management of rare lipodystrophy syndromes, focusing on both generalized and partial forms of the condition.
- Generalized Lipodystrophy Treatment
- Partial Lipodystrophy Management
- Pediatric Metabolic Disorders
Particular attention is given to early intervention strategies in young patients under 6 years of age.
Endocrine Complications
The investigator addresses associated metabolic complications including diabetes mellitus and hypertriglyceridemia in lipodystrophy patients.
- Metabolic Regulation
- Endocrine System Disorders
- Lipid Metabolism
Focus extends to long-term therapeutic outcomes and metabolic control in affected individuals.
Treatment Innovation
Expertise centers on the application of metreleptin therapy for treating various forms of lipodystrophy and associated metabolic complications.
- Therapeutic Efficacy Assessment
- Treatment Safety Monitoring
- Immunogenicity Evaluation
The investigator evaluates both short-term and extended treatment outcomes over 24-month periods.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.